Fig. 8.
Experimental data (open circles) versus fit (solid line) of the temoporfin-to-lipid ratio ρ(c)=ρ0(1−2bc2/kBT)ρ(c)=ρ0(1−2bc2/kBT) for fluid POPC/POPG–liposomes, where c is the liposome curvature and ρ is the cholesterol/lipid fraction. The fitting parameters are ρ0 = 0.06 ± 0.002 and b/(kBT nm2) = −33 ± 10. The inset re-plots the experimental data and the corresponding fit as function of liposome diameter D.
Figure options
For cholesterol (Fig. 7), fitting the experimental data yields ρ0 = 0.09 ± 0.001 and b/(kBT nm2) = 50 ± 15. The molar drug-to-lipid ratio that Fostamatinib was employed for liposome preparation was 0.08 and the experimentally obtained value was 0.087 (see Section 4.2). Hence, theoretical and experimental values for ρ0 agree well. Most significantly, b > 0 is positive, implying that the addition of cholesterol renders the liposomal membrane more rigid. For temoporfin ( Fig. 8) the fitting parameters are ρ0 = 0.06 ± 0.002 and b/(kBT nm2) = −33 ± 10. The average molar drug-to-lipid ratio expressed by ρ0 = 0.06 correlates well with the experimentally found ratio of 0.063 (see Section 4.2). In contrast to cholesterol, the parameter b ≈ −30 kBT nm2 is negative, implying that the drug molecule exerts a softening effect onto the liposomal membrane.